A review on pharmacological options for the treatment of erectile dysfunction: state of the art and new strategies

IntroductionErectile dysfunction (ED) affects between 12.9% and 28.1% of men worldwide, presenting a strong aged-correlated prevalence. Several pharmacological treatments are currently available for ED, which can be classified into oral, injection, and topical/intraurethral therapies.Areas coveredExtensive research on PubMed/MEDLINE until February 2023 was performed. For each of the aforementioned drug classes, available molecules, and formulations, their efficacy and most common adverse events as well as general guidelines on prescription were investigated and extensively described. A glimpse into future directions regarding ED pharmacotherapy is also present.Expert opinionIn recent years, there have been significant developments in pharmacological treatments for ED. It is essential for physicians to identify the best treatment option for patients based on their preferences and sexual habits. The treatment approach for ED has shifted from a sequential to a parallel paradigm, where all treatment options are available as first-line therapies. While there are promising regenerative therapies for ED, such as shockwaves and platelet-rich plasma injections, pharmacological treatment is still the most effective option for most patients.

Automated summary

Erectile dysfunction (ED) affects a significant percentage of men worldwide, with a strong correlation to aging. Various pharmacological treatments, including oral, injection, and topical/intraurethral therapies, are available for ED. This study provides a comprehensive overview of these treatment options, including available drugs and formulations, their effectiveness, common adverse events, and prescription guidelines. Future directions in ED pharmacotherapy are also discussed.